Featured Press Releases

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

  • 02 May 2025

S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has...

Bruker has acquired Dynamic Biosensors, a pioneer in single-cell interaction cytometry systems, aimed at enhancing drug discovery efforts

Bruker has acquired Dynamic Biosensors, a pioneer in single-cell interaction cytometry systems, aimed at enhancing drug discovery efforts

Avantor® Expands Stability and Microbial Testing Facility to Enhance U.S. Biomanufacturing Infrastructure

Avantor® Expands Stability and Microbial Testing Facility to Enhance U.S. Biomanufacturing Infrastructure

Peter Menziuso named EVP and President of BD Interventional

Peter Menziuso named EVP and President of BD Interventional

Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

  • Johnson & Johnson
  • 25 Jun 2026
StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

  • StatLab Medical Products
  • 25 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

  • Zeta Surgical
  • 23 Jun 2026
Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

  • Upsher-Smith Laboratories, LLC
  • 23 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.